These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10065352)

  • 1. Controlled-release hydrophilic tablets for individualized theophylline therapy.
    Sabnis S; Adeyeye CM
    Drug Dev Ind Pharm; 1999 Feb; 25(2):187-96. PubMed ID: 10065352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zero-order release of theophylline from a core-in-cup tablet in sequenced simulated gastric and intestinal fluid.
    Danckwerts MP; van der Watt JG; Moodley I
    Drug Dev Ind Pharm; 1998 Feb; 24(2):163-7. PubMed ID: 15605446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
    Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
    Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs.
    Bach JE; Kukanich B; Papich MG; McKiernan BC
    J Am Vet Med Assoc; 2004 Apr; 224(7):1113-9. PubMed ID: 15074856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of sustained release and conventional tablets of theophylline plus hydroxyethyltheophylline and its comparison with tablet aminophylline.
    Gupta S; Raina RK; Samotra K; Gupta KL
    Indian J Chest Dis Allied Sci; 1991; 33(1):1-8. PubMed ID: 1791015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic evaluation in dogs of theophylline in a novel zero-order release core-in-cup tablet.
    Danckwerts MP; van der Watt JG; Moodley I
    Biopharm Drug Dispos; 1998 Nov; 19(8):517-22. PubMed ID: 9840213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of honey locust (Gleditsia triacanthos Linn.) gum as sustaining material in tablet dosage forms.
    Uner M; Altinkurt T
    Farmaco; 2004 Jul; 59(7):567-73. PubMed ID: 15231434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.
    Hussein Z; Friedman M
    Pharm Res; 1990 Nov; 7(11):1167-71. PubMed ID: 2293217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and evaluation of a controlled-release theophylline tablet. Preliminary communication.
    Gai MN; Pezoa R; Corbeaux J; Arancibia A
    Farmaco; 1989 Nov; 44(11):1119-26. PubMed ID: 2701966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calculation of the dimensions of dosage forms with release controlled by diffusion for in vivo use.
    Ainaoui A; Siepmann J; Bodmeier R; Vergnaud JM
    Eur J Pharm Biopharm; 2001 Jan; 51(1):17-24. PubMed ID: 11154899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse.
    Goetz TE; Munsiff IJ; McKiernan BC
    J Vet Pharmacol Ther; 1989 Dec; 12(4):369-77. PubMed ID: 2614856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of theophylline. Repeated single evening administration of Pulmo-Timelets slow-release capsules in comparison with theophylline slow-release tablets].
    Heusinger JH; Breuel HP; Behrendt WA; Wolfstädter HD
    Fortschr Med; 1989 Nov; 107(32):692-6. PubMed ID: 2689314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invivo absorption behaviour of theophylline from starch-methyl methacrylate matrix tablets in beagle dogs.
    Fernández-Campos F; Ferrero C; Colom H; Jiménez-Castellanos MR
    Int J Pharm; 2015 Jan; 478(2):684-92. PubMed ID: 25476254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
    Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations.
    Korang-Yeboah M; Rahman Z; Shah D; Mohammad A; Wu S; Siddiqui A; Khan MA
    Int J Pharm; 2016 Feb; 499(1-2):20-28. PubMed ID: 26688036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative dose study of a theophylline sustained-release tablet formulation after repeated administrations.
    Cova D; Cuglituri G; Rossini L; Bonfardeci G
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):273-5. PubMed ID: 2737795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled release from directly compressible theophylline buccal tablets.
    Boyapally H; Nukala RK; Bhujbal P; Douroumis D
    Colloids Surf B Biointerfaces; 2010 Jun; 77(2):227-33. PubMed ID: 20188529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronopharmacokinetics of theophylline administered as a controlled-release tablet.
    Thielemann AM; Manquez N; Pinilla E; Gai MN; Romero P; Arancibia A; Chavez H
    Int J Clin Pharmacol Ther; 1996 Mar; 34(3):130-3. PubMed ID: 8705090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained release of theophylline from hydroxypropylcellulose tablets.
    Nakano M; Ohmori N; Ogata A; Sugimoto K; Tobino Y; Iwaoku R; Juni K
    J Pharm Sci; 1983 Apr; 72(4):378-80. PubMed ID: 6864473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.
    Ochoa L; Igartua M; Hernández RM; Solinís MA; Gascón AR; Pedraz JL
    Eur J Pharm Biopharm; 2010 Jun; 75(2):232-7. PubMed ID: 20159037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.